5-HT2B antagonist-1 is an orally active 5-HT2B receptor antagonist with an IC 50 of 33.4 nM. It can be used in studies of diseases characterized by 5-HT2B receptor signaling, such as hepatocellular carcinoma, cardiovascular disease or gastrointestinal disease [1] [2].
5-HT2B antagonist-1 (compound 5g) has some sodium channel binding activity with IC 50 values ranging from 12.6 to 57.5 μM [1]. 5-HT2B antagonist-1 (coumpound 1-e) inhibits 5-HT2B receptor activity by less than 50% at 1 μM in CHO-K1 cell lines [3].